CTLA-4 (CD152): A versatile receptor for immune-based therapy
Holger Lingel1, Monika C Brunner-Weinzierl1
1Department of Experimental Pediatrics, University Hospital, Health Campus Immunology, Infectiology and Inflammation, Otto-von-Guericke-University Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, Germany.
Abstract:
Coreceptor-based immunotherapy is a rapidly developing approach to treat cancer patients. Among those targeted receptors, CTLA-4 is the primary attenuator of adaptive immune responses and the most prominent and extensively investigated molecule in this field. CTLA-4 is involved in broad range of mechanisms that regulate and control immune cell functions and therefore provides versatile strategies for therapeutic interventions. Despite being successfully harnessed in clinical treatments the different facets of CTLA-4 biology still remain incompletely understood. Here, we review the various aspects of CTLA-4 functions and CTLA-4-based immunotherapies and discuss challenges to improve current approaches.
Insights
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a key regulator of immune responses and a target for cancer immunotherapy. Further understanding CTLA-4 biology is crucial for improving existing cancer treatments.
Area of Science:
- Immunology
- Oncology
- Cancer Immunotherapy
Background:
- Coreceptor-based immunotherapy is a rapidly advancing cancer treatment strategy.
- Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a critical attenuator of adaptive immune responses.
- CTLA-4 plays a significant role in regulating immune cell functions, offering therapeutic intervention possibilities.
Purpose of the Study:
- To review the diverse functions of CTLA-4.
- To examine CTLA-4-based immunotherapies.
- To discuss challenges and potential improvements for current CTLA-4-targeted approaches.
Main Methods:
- Literature review of CTLA-4 functions.
- Analysis of clinical data for CTLA-4-based immunotherapies.
- Discussion of unresolved aspects of CTLA-4 biology.
Main Results:
- CTLA-4 is a prominent and extensively studied molecule in cancer immunotherapy.
- CTLA-4 is successfully utilized in clinical treatments.
- Despite clinical success, the complete biology of CTLA-4 remains incompletely understood.
Conclusions:
- CTLA-4-based immunotherapies represent a promising area in cancer treatment.
- Further research into CTLA-4 functions is needed to optimize therapeutic strategies.
- Addressing the gaps in understanding CTLA-4 biology will enhance its clinical application.
Related Concept Videos
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Tumor Immunotherapy


